Skip to content
sellWeak cluster of 2

Octavio Espinoza sold $12k of LGND

Chief Financial Officer at LIGAND PHARMACEUTICALS INC. 140 shares at an average of $88.46, traded Feb 28, 2024, filed Feb 29, 2024.

Warning score
15
Value
$12k
140 shares
Holdings after
29,755
-0% from before
From 52-week low
+70%
low $49.57, close $84.35
From 52-week high
-5%
high $89.20, as of Feb 28, 2024

Score components

  • Role
    CFO
    +22
  • Trade size
    $12k at market
    0
  • Share of holdings sold
    Sold 0.5% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

LGNDOct 12, 2026 · close 311.13
Since filing Feb 29, 2024: +292.1%SPY +58.1% · excess +234.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0002001011-24-000028, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 27, 2024AGrant or award
Common Stock
+7,208$0.00$028,631Feb 29, 2024
Feb 28, 2024MOption exercise
Common Stock
+799$55.75$45k29,430Feb 29, 2024
Feb 28, 2024MOption exercise
Common Stock
+140$57.22$8,01129,570Feb 29, 2024
Feb 28, 2024MOption exercise
Common Stock
+325$58.49$19k29,895Feb 29, 2024
Feb 28, 2024SOpen-market sale
Common Stock
-140$88.46$12k29,755Feb 29, 2024
Feb 28, 2024MOption exercise
Employee Stock Option (right to buy)derivative
-799$0.00$02,869Feb 29, 2024
Feb 28, 2024MOption exercise
Employee Stock Option (right to buy)derivative
-140$0.00$07,722Feb 29, 2024
Feb 28, 2024MOption exercise
Employee Stock Option (right to buy)derivative
-325$0.00$01,607Feb 29, 2024
Feb 27, 2024AGrant or award
Employee Stock Option (right to buy)derivative
+29,272$0.00$029,272Feb 29, 2024

Related signals

Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
10Weak
LGNDsell10b5-1
LIGAND PHARMACEUTICALS INC
Andrew Reardon
CLO & Secretary
$1.5M
5,000 shares
-14%
43Moderate
LGNDsell 2
LIGAND PHARMACEUTICALS INC
Martine Zimmermann
director
$342k
1,200 shares
-24%
33Weak
LGNDsell 210b5-1
LIGAND PHARMACEUTICALS INC
Andrew Reardon
CLO & Secretary
$1.4M
5,000 shares
-12%
47Moderate
LGNDsell 310b5-1
LIGAND PHARMACEUTICALS INC
Octavio Espinoza
Chief Financial Officer
$9.2M
31,641 shares
-53%
60Notable
LGNDsell 3
LIGAND PHARMACEUTICALS INC
Jason Haas
director
$2.1M
7,138 shares
-64%
25Weak
LGNDsell 310b5-1
LIGAND PHARMACEUTICALS INC
Andrew Reardon
CLO & Secretary
$1.4M
5,000 shares
-11%
10Weak
LGNDsell10b5-1
LIGAND PHARMACEUTICALS INC
Andrew Reardon
CLO & Secretary
$1.6M
5,000 shares
-11%
34Weak
LGNDsell 4
LIGAND PHARMACEUTICALS INC
Stephen L Sabba
director
$545k
2,145 shares
-6%
60Notable
LGNDsell 5
LIGAND PHARMACEUTICALS INC
Jason Haas
director
$1.7M
6,461 shares
-56%
55Moderate
LGNDsell 5
LIGAND PHARMACEUTICALS INC
Jason Aryeh
director
$1.3M
5,000 shares
-5%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Octavio Espinoza sold $12k of LGND | InsiderTell